

# PRECEPTORSHIP PROGRAMME

## Non-Small-Cell Lung Cancer (NSCLC)

Standards of care, evolving paradigm  
and future perspectives

**SINGAPORE**

**15-16 NOVEMBER 2017**

Co-Chairs    Jean-Yves Douillard, CH  
                    Ross A. Soo, SG

# ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Singapore  
15-16 November 2017

---

CO-CHAIRS: Jean-Yves Douillard, Switzerland  
Ross A. Soo, Singapore

SPEAKERS: Jaafar Bennouna, France  
Dominique Grunenwald, France  
Eiji Iwama, Japan  
Keith Kerr, United Kingdom  
Tony S. K. Mok, Hong Kong  
Egbert F. Smit, Netherlands  
Ivan Tham, Singapore

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology and histoprognostic factors in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC

---

## ACCREDITATION

The programme of this event has been accredited with 7 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Luigi Taddei 4  
6962 Lugano - Viganello  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 15 November 2017

<b>13:00-14:00</b>	<b>Lunch</b>	
14:00-14:15 15'	Opening and welcome	Chair: Jean-Yves Douillard, CH
15'	Welcome from ESMO, objectives and scientific introduction	Jean-Yves Douillard, CH
14:15-16:15 120'	<b>SESSION 1</b> Non-metastatic disease	Chair: Ross A. Soo, SG
30'	Histopathology of NSCLC, IHC markers and pTNM classification	Keith Kerr, UK
20'	State-of-the-art: Standard of care for resectable NSCLC - Surgical approach for resectable NSCLC	Dominique Grunenwald, FR
40'	State-of-the-art: Standard of care for resectable NSCLC - Adjuvant chemotherapy - Is there a place for neoadjuvant chemotherapy?	Jaafar Bennouna, FR
30'	State-of-the-art for locally advanced unresectable / inoperable disease NSCLC: - Post-Operative Radiation Therapy (PORT) in resected N2 NSCLC - Update on RT / CT for unresectable NSCLC - Stereotactic RT and IMRT for inoperable NSCLC	Ivan Tham, SG
<b>16:15-16:45</b>	<b>Coffee break</b>	
16:45-17:45 60'	<b>SESSION 2</b> Audience cases	Chair: Jean-Yves Douillard, CH
3x20'	3 x Participant clinical case discussion	Faculty
<b>20:00</b>	<b>Dinner</b>	

## Thursday, 16 November 2017

09:00-10:30 90'	<b>SESSION 3</b> Metastatic NSCLC	Chair: Jaafar Bennouna, FR
30'	1 <sup>st</sup> line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC	Ross A. Soo, SG
30'	Immunotherapy	Jean-Yves Douillard, CH
30'	Maintenance treatment: chemo maintenance or targeted agents or both?	Egbert F. Smit, NL
<b>10:30-11:00</b>	<b>Coffee break</b>	
11:00-12:10 70'	<b>SESSION 4</b> Biomarker driven treatment	Chair: Egbert F. Smit, NL
30'	Biomarker driven treatment of selected NSCLC: EGFR - EGFR TKI in mutant EGFR NSCLC - Mechanisms of resistance and new generation EGFR TKI	Jaafar Bennouna, FR
20'	Tissue or liquid biopsies? For diagnosis, monitoring and early detection of resistance	Eiji Iwama, JP
20'	Biomarkers driven treatment of selected NSCLC: ALK EML4 - Crizotinib - Crizotinib resistance - 2 <sup>nd</sup> generation drugs	Tony S. K. Mok, HK

12:10-13:10	Lunch	
13:10-13:55 45'	SESSION 5 Future developments	Chair: Ross A. Soo, SG
30'	Strategic approaches: - Sequence of use of targeted agents and chemotherapy and definition of progression under TKI - Intercalating anti-EGFR with chemotherapy	Tony S. K. Mok, HK
15'	2 <sup>nd</sup> and later lines of treatment	Egbert F. Smit, NL
13:55-14:55 60'	SESSION 6 Audience cases	Chair: Ross A. Soo, SG
3x20'	3 x Participant clinical case discussion	Faculty
14:55-15:10 15'	Conclusion and take home messages	Ross A. Soo, SG

**Note:** Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / panel discussion